Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics

被引：0
|
作者：
Azaro, A. [1 ]
Rodon, J. [1 ]
Vansteenkiste, J. F. [2 ]
Ando, Y. [3 ]
Doi, T. [4 ]
Mills, D. [5 ]
Sarr, C. [6 ]
Di Tomaso, E. [7 ]
Massacesi, C. [8 ]
Naumann, R. W. [9 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Univ Hosp Gasthuisberg, Resp Oncol Unit, B-3000 Louvain, Belgium
[3] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp, Gastrointestinal Oncol Div, Chiba, Japan
[5] Novartis Pharma AG, Stat, Basel, Switzerland
[6] Novartis Pharma AG, Modeling, Basel, Switzerland
[7] Novartis Inst Biomed Res, Cambridge, MA USA
[8] Novartis Oncol, Global Clin Program, Paris, France
[9] Carolinas Med Ctr, Div Gynecol Oncol, Charlotte, NC 28203 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
884
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [1] Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
    Matas-Cespedes, Alba
    Rodriguez, Vanina
    Kalko, Susana G.
    Vidal-Crespo, Anna
    Rosich, Laia
    Casserras, Teresa
    Balsas, Patricia
    Villamor, Neus
    Gine, Eva
    Campo, Elias
    Roue, Gael
    Lopez-Guillermo, Armando
    Colomer, Dolors
    Perez-Galan, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3458 - 3471
  • [2] Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Schindler, Katja
    Abraham, Ronnie
    Shah, Payal Deepak
    Chandarlapaty, Sarat
    Palk, Paul K.
    Bell-McGuinn, Katherine
    Bajorin, Dean F.
    Mellinghoff, Ingo K.
    Younes, Anas
    Gounder, Mrinal M.
    Fury, Matthew G.
    Busam, Klaus J.
    Dickler, Maura N.
    Lacouture, Mario E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A phase I dose-escalation study of buparlisib (BKM120), an oral pan-PI3K inhibitor, in Chinese patients with advanced solid tumors
    Zhang, L.
    Xu, B.
    Hazell, K.
    Gaur, A.
    Xu, J.
    Trandafir, L.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S186
  • [4] Buparlisib is a brain penetrable pan-PI3K inhibitor
    Mark C. de Gooijer
    Ping Zhang
    Levi C. M. Buil
    Ceren H. Çitirikkaya
    Nishita Thota
    Jos H. Beijnen
    Olaf van Tellingen
    Scientific Reports, 8
  • [5] Buparlisib is a brain penetrable pan-PI3K inhibitor
    de Gooijer, Mark C.
    Zhang, Ping
    Buil, Levi C. M.
    Citirikkaya, Ceren H.
    Thota, Nishita
    Beijnen, Jos H.
    van Tellingen, Olaf
    SCIENTIFIC REPORTS, 2018, 8
  • [6] Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance
    Safaroghli-Azar, Ava
    Bashash, Davood
    Kazemi, Alireza
    Pourbagheri-Sigaroodi, Atieh
    Momeny, Majid
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 842 : 89 - 98
  • [7] Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer
    Geuna, Elena
    Milani, Andrea
    Martinello, Rossella
    Aversa, Caterina
    Valabrega, Giorgio
    Scaltriti, Maurizio
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (03) : 421 - 431
  • [8] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [9] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [10] A PHASE I DOSE ESCALATION AND EXPANSION TRIAL OF BKM120, AN ORAL PAN-PI3K INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS: ANALYSIS OF PHARMACODYNAMIC BIOMARKER DATA
    Rodon, J.
    Bendell, J.
    Razak, A. R. A.
    De Jonge, M. J. A.
    Eskens, F.
    Di Tomaso, E.
    Sternberg, D. W.
    Wang, L.
    Sarr, C.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 159
12345